Medpace Holdings (MEDP) EBIT (2015 - 2026)

Medpace Holdings (MEDP) has reported EBIT for 12 consecutive years, with $146.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 16.22% year-over-year to $146.8 million; the trailing twelve-month figure through Jun 2026 stood at $583.4 million (up 22.18% YoY), and the FY2025 full-year result was $534.9 million, up 19.71% from the prior year.
• EBIT climbed to $146.8 million in Q2 2026 per MEDP's latest filing, from $141.5 million in the prior quarter.
• Across five years, EBIT topped out at $153.3 million in Q4 2025 and bottomed at $60.2 million in Q2 2022.
• Historically, EBIT has averaged $104.8 million across 5 years, with a median of $104.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: EBIT surged 44.89% in 2022, then climbed 9.08% in 2025.
• Over 5 years, EBIT stood at $76.4 million in 2022, then rose by 14.25% to $87.3 million in 2023, then soared by 43.58% to $125.4 million in 2024, then gained by 22.25% to $153.3 million in 2025, then fell by 4.21% to $146.8 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $146.8 million, $141.5 million, and $153.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.